IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,622 shares of the company's stock after selling 7,012 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in IDEXX Laboratories were worth $9,353,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of IDXX. Geode Capital Management LLC raised its stake in shares of IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after buying an additional 37,734 shares in the last quarter. Bamco Inc. NY grew its holdings in IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after acquiring an additional 82,264 shares during the period. Invesco Ltd. raised its position in IDEXX Laboratories by 6.8% in the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after acquiring an additional 74,324 shares in the last quarter. Norges Bank acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $412,258,000. Finally, Northern Trust Corp lifted its holdings in IDEXX Laboratories by 18.6% in the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company's stock valued at $377,419,000 after acquiring an additional 143,369 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total value of $537,372.04. Following the completion of the sale, the director now directly owns 262 shares of the company's stock, valued at approximately $134,599.88. The trade was a 79.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Stifel Nicolaus increased their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday. Piper Sandler upped their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded up $1.44 during trading on Monday, hitting $514.80. 501,699 shares of the company were exchanged, compared to its average volume of 651,993. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $530.60. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average price of $449.80 and a 200 day moving average price of $437.41. The stock has a market capitalization of $41.40 billion, a price-to-earnings ratio of 48.25, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the previous year, the firm posted $2.71 earnings per share. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.